Has David Lichten, MD received payments from drug or device companies?

Yes. Drug and device makers reported $117,080 in general payments to David Lichten, MD across 340 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Lichten, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Lichten, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Lichten, MD

Physical Medicine & Rehabilitation · Reading, PANPI 1366563744

Payments from drug & device makers

$117,080in general payments, 2019–2025

Across 340 payments — averaging $344.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

MDD US Operations, LLC$88K
Pacira Therapeutics, Inc.$21K
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
Collegium Pharmaceutical, Inc.$571
Amgen$448
Scilex Pharmaceuticals Inc.$439
plus $2K from 32 others

What the payments were for

Consulting fees$4,9304%
Speaking & faculty fees$100,15086%
Travel & lodging$6,0345%
Food & beverage$5,9665%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
MDD US Operations, LLC	144	$88,395
Pacira Therapeutics, Inc.	26	$20,631
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	10	$4,120
Collegium Pharmaceutical, Inc.	26	$571
Amgen	20	$448
Scilex Pharmaceuticals Inc.	20	$439
Abbott	17	$430
Boston Scientific	13	$332
Vertos Medical, Inc.	2	$286
Nevro Corp.	3	$163
AbbVie	7	$160
Biodelivery Sciences International, Inc.	3	$140
Almatica Pharma LLC	7	$125
Tersera Therapeutics LLC	5	$104
Saluda Medical Americas, Inc.	2	$98
Ipsen Biopharmaceuticals, Inc	4	$87
Averitas Pharma Inc.	3	$56
Medtronic	2	$54
Azurity Pharmaceuticals, Inc.	3	$46
Si-bone, Inc.	1	$37
Assertio Therapeutics, Inc.	2	$32
Foundation Fusion Solutions, LLC	2	$32
Biohaven Pharmaceuticals, Inc.	1	$32
Zyla Life Sciences, Inc.	2	$27
Bioventus LLC	1	$26
Kowa Pharmaceuticals America, Inc.	2	$26
Fidia Pharma USA Inc.	1	$25
Pacira Pharmaceuticals Incorporated	1	$17
ERMI LLC	1	$16
Vertex	1	$16
IBSA Pharma Inc.	1	$15
GRT US Holding, Inc.	1	$15
Appliedvr Inc	1	$14
Arbor Pharmaceuticals, Inc.	1	$14
Electronic Waveform Lab, Inc.	1	$13
Pfizer	1	$13
West Therapeutics Development, LLC	1	$13
Vertical Pharmaceuticals, LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,080 in reported general payments places this provider in the 95th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

See all physical medicine & rehabilitation providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$377,322

Medicare patients

335

Services billed

8,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin ErGabapentin	11	$8,431
Gabapentin	139	$1,245
Pregabalin	19	$561
Duloxetine Hcl	11	$537
Tramadol Hcl ErTramadol Hcl	13	$522
Tramadol Hcl	57	$302
Meloxicam	90	$252
Prednisone	55	$223
Morphine Sulfate ErMorphine Sulfate	12	$208
Oxycodone Hcl	15	$152
Cyclobenzaprine Hcl	29	$127
Ibuprofen	16	$74
Eszopiclone	12	$70
Pantoprazole Sodium	13	$63
Famotidine	11	$48

Paid to pharmacies, not to this prescriber.

Other physical medicine & rehabilitation in Reading

Cameron OlezenePhiladelphia$4.1M
Jeffery RoweKing Of Prussia$2M
Michael SaulinoElkins Park$502K
Alberto EsquenaziPhiladelphia$465K
Huaguang QuChalfont$426K
Michael MuninPittsburgh$412K
Scott DavidoffKing Of Prussia$365K
Mitchell PaulinPaoli$229K
Natasha RomanoskiHummelstown$139K
Kimberly HeckertPhiladelphia$119K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →